Valsartan
Valsartan has been studied in 24 papers since 2009: 3 trials and 5 observational studies in people, 8 in animals, 4 in cells, 2 reviews; 9 in the past year. It is an approved medicine. The newest paper, Oct 26, 2026: “Risk of incident gout and major adverse cardiovascular events according to angiotensin receptor blocker type in amlodipine-based combination therapy:…”.
11 new papers in 30 daysSee all 47 papers on valsartan
At a glance
The findings reach people, from one lab or study; independent labs found the same change in cells. 10 independent labs in 7 countries; 273 trials, 12 about aging, 128 with no results posted.
“Both fluvastatin and valsartan alone significantly, but to a lesser extent, increased the expression of SIRT1”
None of its findings points the other way.
- 10 independent labs in 7 countries
- 273 trials, 12 about aging, 128 with no results posted
- Funders: Johns Hopkins University and others
- 1 of 16 findings with company ties
- 145 of 273 trials sponsored by its developers
- Human trial3
- Humans5
- Animals8
- Cells4
- In silico1
Studies in people
1 study gave valsartan to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases immune activation-related transcripts in low-density neutrophils | Trialone month | Newly diagnosed hypertension | European journal of pharmacology, Jan 31, 2026 |
What did studies of valsartan find?
15Studies of valsartan measured 15 outcomes, among them cellular senescence, wound healing and gout.
Cellular senescence
downin human cells1downin mouse cells1
2 studies
Cellular senescence
downin human cells1downin mouse cells1
Valsartan decreases cellular senescence in combined lower-dose Ang II and Aβ treatment.
Cellsin combined lower-dose Ang II and Aβ treatmentbrain vascular smooth muscle cellmales
Valsartan decreases cellular senescence in Ang II-treated cells, co-treated with valsartan.
Cellsin Ang II-treated cells, co-treated with valsartan
Wound healing
upin mice1upin pigs1
1 study
Wound healing
upin mice1upin pigs1
Valsartan improves wound healing in pigs (older diabetic pigs).
Animalsolder diabetic pigs1% topical gelskin1%
Valsartan improves wound healing in mice (diabetic and aged mice).
Animalsdiabetic and aged mice1% topical gelskin1%
Gout
no changein humans1HR 1.015
1 study
Gout
no changein humans1HR 1.015
Valsartan was not clearly linked with gout in humans (Newly diagnosed hypertension; combined with amlodipine; compared with non-persistent users) (HR 1.015, 95% CI 0.985–1.045).
HumansNewly diagnosed hypertension; combined with amlodipine; compared with non-persistent users5 years
LDL cholesterol
downin silico1
1 study
LDL cholesterol
downin silico1
Valsartan decreases LDL cholesterol in silico (β = -2.34 × 10 -3).
In silico
Hypertension
downin mice1
1 study
Hypertension
downin mice1
Valsartan decreases hypertension in tacrolimus-treated mice.
Animalsin tacrolimus-treated mice
Microvascular remodeling
downin mice1
1 study
Microvascular remodeling
downin mice1
Valsartan decreases microvascular remodeling in tacrolimus-treated mice.
Animalsin tacrolimus-treated mice
Immune activation-related transcripts in low-density neutrophils
downin humans1
1 study
Immune activation-related transcripts in low-density neutrophils
downin humans1
Valsartan decreases immune activation-related transcripts in low-density neutrophils in humans (newly diagnosed hypertension).
Human trialnewly diagnosed hypertensionlow-density neutrophil80 mg/dayone month
More on Immune activation-related transcripts in low-density neutrophils
NLRP3
no changein rats1
1 study
NLRP3
no changein rats1
Valsartan showed no clear effect on NLRP3 in OVX rats.
Animalsin OVX ratshippocampus40 mg/kg/dayfemales
BDNF
upin rats1
1 study
BDNF
upin rats1
Valsartan increases BDNF in OVX rats.
Animalsin OVX ratshippocampus40 mg/kg/dayfemales
Oxidative stress and ROS signaling
downin rats1
1 study
Oxidative stress and ROS signaling
downin rats1
Valsartan decreases oxidative stress and ROS signaling in OVX rats.
Animalsin OVX ratshippocampus40 mg/kg/dayfemales
SIRT1
upin humans1
1 study
SIRT1
upin humans1
Valsartan increases SIRT1 in humans.
Human trial20 mg daily30 daysmales
All 15Fewer
What is valsartan linked with?
2Studies link valsartan with 2 measures: cough and transient cerebral ischemic attack.
Cough
upin silico1
1 study
Cough
upin silico1
Valsartan raises the risk of cough in silico (odds ratio = 1.67).
In silico
Transient cerebral ischemic attack
downin silico1
1 study
Transient cerebral ischemic attack
downin silico1
Valsartan lowers the risk of transient cerebral ischemic attack in silico.
In silico
Has valsartan been tested in people?
12 of 273 about agingYes: 3 trials and 5 observational studies in people have been published, and 252 trials are registered.
About aging
Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome
Phase 4Completed
Phase 4Completed
Phase 3Completed
Phase 3Completed
Phase 3Completed
Phase 3Completed
All 12Fewer
Approved
Dec 23, 1996Discontinued
Jul 18, 2001Heart Failure, Hypertension, Myocardial Infarction, Ventricular Dysfunction, Left, high blood pressure, Post Myocardial Infarction
Dec 19, 2017Heart Failure, Hypertension, Myocardial Infarction, Ventricular Dysfunction, Left, high blood pressure, Post Myocardial Infarction
Repurposing
Phase 4Results posted2 trials
Phase 4Results posted7 trials
Phase 4Completed9 trials
Phase 4Completed8 trials
Phase 4Results posted4 trials
Phase 4Completed2 trials
40 of 83Fewer
Every condition in trials
Motor Activity
Phase 4Completed2 trials
Respiratory distress syndrome
Phase 4Terminated2 trials
Hyperlipidemias
Phase 3Results posted5 trials
De novo renal transplantation
Phase 3Completed1 trial
Hypertension with hyperlipidemia
Phase 3Completed1 trial
Overweight subject
Phase 1Recruiting1 trial
Readouts due
- Apr 2027
Enhancing the Natriuretic Peptide System in HFpEF
Phase 1/2Enrolling by invitation
- Apr 30, 2027
Stopped
NCT02787798TerminatedHeart failure
Today Entresto treatment has marketing authorization and is available for all patients, that is the reason why study was halted prematurely.
NCT00200694TerminatedProteinuria
difficulty in patients's inclusion
NCT04335786TerminatedCOVID-19
Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the REMAP-CAP trial.
NCT00343499TerminatedAtrial fibrillation
Inability to recruit
NCT01805804TerminatedVentricular remodeling
Recall of some valsartan preparations. 88 patients enrolled and completed the observation. All patients are in continuous observation and are well.
NCT04606563TerminatedAcute kidney injury
DSMC recommendation due to futility
Who is developing valsartan?
3 companies: Novartis Pharmaceuticals, Shandong New Time Pharmaceutical and Novartis.
Trial sponsors
Company79 trialsPhase 441,515 people
Novartis Pharmaceuticals Corporation
Company40 trialsPhase 434,362 people
Company4 trialsPhase 43,669 people
Company1 trialPhase 4365 people
Company1 trialPhase 4252 people
Company1 trialPhase 493 people
Company1 trialPhase 436 people
Company1 trialPhase 420 people